<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATE AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g)
OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE
REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 000-28844
Algos Pharmaceutical Corporation
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
1333 Campus Parkway, Neptune, New Jersey 07753-6815, (732) 938-5959
--------------------------------------------------------------------------------
(Address, including zip code, and telephone number, including area code,
of registrant's principal executive offices)
Common Stock, $0.01 par value
--------------------------------------------------------------------------------
(Title of each class of securities covered by this Form)
None
--------------------------------------------------------------------------------
(Titles of all other classes of securities for which a duty to file reports
under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [x] Rule 12h-3(b)(1)(i) [x]
Rule 12g-4(a)(1)(ii) [ ] Rule 12h-3(b)(1)(ii) [ ]
Rule 12g-4(a)(2)(i) [ ] Rule 12h-3(b)(2)(i) [ ]
Rule 12g-4(a)(2)(ii) [ ] Rule 12h-3(b)(2)(ii) [ ]
Rule 15d-6 [ ]
Approximate number of holders of record as of the certification or notice
date:
Common Stock, par value $0.01 per share: 1
Pursuant to the requirements of the Securities Exchange Act of 1934, Algos
Pharmaceutical Corporation has caused this certification/notice to be signed on
its behalf by the undersigned duly authorized person.
Date: July 17, 2000 By: /s/ John W. Lyle
--------------------------------------------
Name: John W. Lyle
Title: President and Chief Executive Officer
